Dorothea Spambalg
Endocrinology, Diabetes & Metabolism · Pasadena, CANPI 1568406809
Payments from drug & device makers
Across 167 payments — averaging $21.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$982
- Lilly USA, LLC$854
- AstraZeneca$701
- Bayer$355
- Xeris Pharmaceuticals, Inc.$149
- Medtronic$102
- plus $408 from 8 others
What the payments were for
- Food & beverage$3,51899%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 52 | $982 |
| Lilly USA, LLC | 42 | $854 |
| AstraZeneca | 31 | $701 |
| Bayer | 14 | $355 |
| Xeris Pharmaceuticals, Inc. | 7 | $149 |
| Medtronic | 3 | $102 |
| IBSA Pharma Inc. | 4 | $83 |
| Insulet Corporation | 4 | $80 |
| Radius Health, Inc. | 3 | $69 |
| Boehringer Ingelheim | 2 | $56 |
| Mannkind Corporation | 2 | $53 |
| Amgen | 1 | $29 |
| Corcept Therapeutics | 1 | $20 |
| Tandem Diabetes Care, Inc. | 1 | $19 |
How this compares
$3,550 in reported general payments places this provider in the 60th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 258 | $269,780 |
| JardianceEmpagliflozin | 201 | $187,523 |
| MounjaroTirzepatide | 133 | $140,172 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 77 | $63,252 |
| TrulicityDulaglutide | 24 | $32,931 |
| JanuviaSitagliptin Phosphate | 29 | $31,187 |
| SynthroidLevothyroxine Sodium | 325 | $29,957 |
| Victoza 3-PakLiraglutide | 14 | $17,287 |
| Liraglutide | 12 | $9,685 |
| HumalogInsulin Lispro | 43 | $9,316 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $2,250 |
| Metformin Hcl ErMetformin Hcl | 104 | $1,804 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $1,671 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 28 | $1,661 |
| LevoxylLevothyroxine Sodium | 44 | $1,645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $982 | $269,780258 claims |
| Boehringer IngelheimJardiance | $56 | $187,523201 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $854 | $183,253213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Pasadena
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
- David AhnNewport Beach$5.8M
- Shlomo MelmedLos Angeles$3.3M
- Leila ChaychiSan Carlos$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.